Literature DB >> 24687838

How to interpret patient preferences in selecting the best drug: are the current measurements up to the job?

Marc B Garnick1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24687838     DOI： 10.1200/JCO.2014.55.1911

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

Review 1.  Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting.

Authors:  Guillermo de Velasco; Lana Hamieh; Suzanne Mickey; Toni K Choueiri
Journal:  Urol Oncol       Date:  2015-10-09       Impact factor: 3.498

2.  Cost-effectiveness of pazopanib: an example of improved transparency and accessibility of industry-sponsored economic evaluations through publication in peer-reviewed journals.

Authors:  J Beca; K K W Chan
Journal:  Curr Oncol       Date:  2016-08-12       Impact factor: 3.677

Review 3.  Pazopanib: a review of its use in the management of advanced renal cell carcinoma.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.